Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases

25Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Protozoan parasites of the order kinetoplastida are the causative agents of three of the world's most important neglected human diseases: African trypanosomiasis, American trypanosomiasis, and leishmaniasis. Current therapies are limited, with some treatments having serious and sometimes lethal side effects. The growing number of cases that are refractory to treatment is also of concern. With few new drugs in development, there is an unmet medical need for new, more effective, and safer medications. Recent studies employing genetic and pharmacological techniques have begun to shed light on the role of the cyclic nucleotide phosphodiesterases in the life cycle of these pathogens and suggest that these important regulators of cyclic nucleotide signaling may be promising new targets for the treatment of parasitic diseases. © 2011 Springer-Verlag Berlin Heidelberg.

Cite

CITATION STYLE

APA

Shakur, Y., De Koning, H. P., Ke, H., Kambayashi, J., & Seebeck, T. (2011). Therapeutic potential of phosphodiesterase inhibitors in parasitic diseases. Handbook of Experimental Pharmacology, 204, 487–510. https://doi.org/10.1007/978-3-642-17969-3_20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free